Forbion Announces its New General Partner

Bos led a team of twenty-one investment professionals at M Ventures, which invested 400 million euros in over 50 portfolio companies ranging from biotech to life sciences tools to IT, with investment activities ranging from seed to cross-over and IPO.

FREMONT, CA: Forbion, a leading European life sciences venture capital firm, announced the addition of Jasper Bos, Ph.D., a former Merck executive, as General Partner for the firm's Growth Fund. Bos was Senior Vice President and Managing Director of M Ventures, the venture arm of pharmaceutical major Merck, before joining Forbions' Naarden headquarters in 2009. He led a team of twenty-one investment professionals at M Ventures, which invested 400 million euros in over 50 portfolio companies ranging from biotech to life sciences tools to IT, with investment activities ranging from seed to cross-over and IPO.

"In light of the recent, sizable final close, at the EUR 360 million hard cap of our Forbion Growth Opportunities Fund I, we are pleased to have a seasoned life sciences investment professional like Jasper joining our growing team. Jasper has overseen four companies through their IPO process, and has vast experience with pharma spin-outs and prominent licensing deals involving diverse stakeholders from big-pharma to leading academic institutions. 

His scientific and financial experience will be instrumental as we continue implementing our strategy which is to enable the most innovative companies bring new impactful treatments and therapies to market," explained Sander Slootweg, Managing Partner, Forbion.

Commenting on his appointment as General Partner, Jasper Bos added, "I am excited to be joining Forbion, in my view one of the leading investment firms in the life sciences space, and to actively contribute to deploying their Growth Opportunities Fund and thus help to grow the market for late-stage European biotech investing in Europe. I look forward to working with the Forbion team, and I am confident that my track record in the industry will be complementary to theirs, especially when it comes to creating pharma spin outs."

Bos has previously worked with the Netherlands Vaccine Institute, the Dutch National Institute of Public Health, and private equity firms. He graduated from the University of Groningen in the Netherlands with a doctorate in pharmacy.